Artivion reports second quarter 2025 financial results

Second quarter highlights: achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a gaap basis and 14% on a non-gaap constant currency basis net income was $1.3 million, or $0.03 per fully diluted share and non-gaap net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025 adjusted ebitda increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024 exchanged $99.5 million in principal amount of outstanding convertible senior notes due july 1, 2025 for common stock, resulting in the effective retirement of previously issued notes received investigational device exemption (ide) approval from the u.s. food and drug administration (fda) to initiate the artizen pivotal trial evaluating the efficacy and safety of arcevo lsa to replace the entire aortic arch for the treatment of acute and chronic arch pathologies atlanta , aug. 7, 2025 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended june 30, 2025. "the second quarter was exceptionally strong as we made progress across each of our strategic initiatives while delivering 14% constant currency revenue growth.
AORT Ratings Summary
AORT Quant Ranking